相关实验视频

Updated: Sep 19, 2025

A High Resolution Method to Monitor Phosphorylation-dependent Activation of IRF3

A High Resolution Method to Monitor Phosphorylation-dependent Activation of IRF3

Published on: January 24, 2016

蛋白质体抑制诱导IRF1下游分子独立于JAK活动在癌症中

Kaito Takahashi¹, Atsushi Takahashi¹, Nana Takahashi¹

¹Department of Cancer Cell Biology, Faculty of Pharmaceutical Sciences, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan.

Biological & pharmaceutical bulletin

|June 18, 2025

概括

蛋白质酶抑制剂通过增加干扰素调节因子1 (IRF1) 表达,独立于氏激酶 (JAK) 活性来提高癌症免疫性. 这种方法可能会提高癌症免疫治疗的有效性.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
药理学药理学是指药理学的学科.

背景情况:

简氏酶1/2 (JAK1/2) 的功能丧失突变通过降低干扰素调节因子1 (IRF1) 诱导来损害瘤免疫性,导致对癌症免疫疗法的反应不佳.
开发能够独立于JAK活性增强IRF1表达的新型试剂对于改善癌症免疫治疗结果至关重要.

研究的目的:

调查蛋白质酶抑制剂在增加独立于JAK活性的IRF1表达方面的潜力.
评估蛋白酶体抑制剂对IRF1下游分子的影响及其对癌症免疫性的影响.

主要方法:

利用了各种癌症类型,包括黑色素瘤.
采用了JAK信号通路的遗传和化学抑制.
评估IRF1表达及其下游目标,包括编程死亡配体1 (PD-L1),PD-L2和人类白细胞抗原I类分子.

主要成果:

蛋白质酶抑制剂在各种癌症类型中以JAK独立的方式激活IRF1下游通路.
蛋白质酶抑制剂通过抑制其在黑色素瘤细胞中的降解来增加IRF1的表达.
PD-L1,PD-L2和人类白细胞抗原I类分子的表达是由蛋白酶体抑制剂诱导的.
通过蛋白质酶抑制剂诱导IRF1被证实是独立于JAK活性.

结论:

蛋白酶体抑制剂可以通过JAK独立的机制通过上调IRF1表达来增强癌症免疫性.
这些发现表明,蛋白酶体抑制剂可以作为有效的辅助剂,以增强癌症免疫疗法的疗效.

关键词:

免疫检查点抑制剂免疫检查点抑制剂干扰素调节因子1 干扰素调节因子1 编程死亡链条 1 编程死亡链条蛋白酶体抑制剂是一种蛋白酶体抑制剂.

更多相关视频

Native Polyacrylamide Gel Electrophoresis Immunoblot Analysis of Endogenous IRF5 Dimerization

Native Polyacrylamide Gel Electrophoresis Immunoblot Analysis of Endogenous IRF5 Dimerization

Published on: October 6, 2019

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

相关概念视频

The JAK-STAT Signaling Pathway

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

Regulation of the Unfolded Protein Response

Regulation of the Unfolded Protein Response

Inositol-requiring kinase one or IRE1 is the most conserved eukaryotic unfolded protein response (UPR) receptor. It is a type I transmembrane protein kinase receptor with a distinctive site-specific RNase activity. As the binding mechanics of the misfolded proteins with the N-terminal domain of IRE-1 are unclear, three binding models — direct, indirect, and allosteric -- are proposed for receptor activation. Nevertheless, it is known that once a misfolded protein associates with IRE1, it...

NF-κB-dependent Signaling Pathway

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...

PI3K/mTOR/AKT Signaling Pathway

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...

MAPK Signaling Cascades

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...